Gastrointestinal neuroendocrine tumor

Disease ID:622
Name:Gastrointestinal neuroendocrine tumor
Associated with:1 target
Database Links
Disease Ontology: DOID:4148

Targets

SST2 receptor
Role:  The randomized, placebo-controlled, prospective PROMID (placebo-controlled, double-blind, prospective randomized study) showed effect of octreotide LAR in the control of tumour growth in patients with metastatic midgut neuroendocrine tumors (NETs).
References:  1

Ligands

No ligand related data available for Gastrointestinal neuroendocrine tumor

References

Show »

1. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M et al.. (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol., 27 (28): 4656-63. [PMID:19704057]